This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
hodgkin-lymphoma
Hodgkin Lymphoma
Hodgkin lymphoma is a GC B cell-derived malignancy; RS cells ~100% CD30+; 9p24.1 amplification drives CD30+PD-L1/L2 co-expression; A+AVD (ECHELON-1) is standard for advanced stage; nivolumab/pembrolizumab for R/R; 5-year OS >85% overall; NLPHL has distinct CD20+ biology.
Entry Metadata
| Field | Value |
|---|---|
| ID | hodgkin-lymphoma |
| Name | Hodgkin Lymphoma |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- Connors JM, Jurczak W, Straus DJ, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma. N Engl J Med. 2018;378(4):331-344. · PubMed 29360494
- Armand P, Engert A, Younes A, et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol. 2018;36(14):1428-1439. · PubMed 29584546